Contents
Finding Trials in Fort Worth
There are prime opportunities for clinical trials in Fort Worth, presently over 300 are available, and more become available all the time. Keep in mind, that Fort Worth is a sister city to Dallas. Provided you can handle the commute, you can double your opportunity. It’s easy to find paid clinical trials for healthy volunteers near you in an urban sprawl like Dallas/Fort Worth.
We’re going to look at Fort Worth specifically to help round out your perspective on available opportunities. Currently, estimates put the population of Fort Worth at 954,457 residents. That number is rising all the time, especially now.
Some estimate that 1 in 200 people need to be continuously involved in paid clinical trials across the country in order to maintain the advancement of medical science. That’s .005%. Statistically, that indicates 4,772+ individual opportunities will likely come and go in the city on an annual basis. Local research facilities like the University of North Texas Health Science Center at Fort Worth often need multiple participants for varying studies, meaning dozens to hundreds of individuals have an opportunity for each study.
Developing Clinical Research Opportunities in Fort Worth
Lots of people find themselves wondering: “are there any paid clinical trials for healthy volunteers near me?”; or something similar. They’re not alone. Definitely, the opportunities exist. Usually, it’s best to seek out Clinical Research Organizations, or CROs. Demographics often help drive local CRO opportunities.
The earlier link to population information also provides some notable demographic data. Caucasians are 60.06%, black citizens comprise 18.54% of the population, while “other race” and “two or more races” constitute 15.99% of the population combined. Expect clinical trials to circulate around these demographics in Fort Worth.
As far as age and gender goes, the median age for Fort Worth is 32.6 for men and 33.3 for women. Females make up 50.99% of the local population, men make up 49.01%. Accordingly, most trials will be geared at younger men and women in the prime of life; however, there will be opportunities for other local populations as well.
International Pediatric Adrenocortical Tumor Registry
Recruiting
This study aims to collect demographic and medical information including detailed family history of cancer of children and adolescents with adrenocortical tumors in order to learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients with this rare disease, worldwide.
In addition, investigators at St. Jude Children's Research Hospital (SJCRH) plan to perform molecular studies of tumor cells aimed to clarify the role of the TP53 gene and other genetic... Read More
This study aims to collect demographic and medical information including detailed family history of cancer of children and adolescents with adrenocortical tumors in order to learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients with this rare disease, worldwide.
In addition, investigators at St. Jude Children's Research Hospital (SJCRH) plan to perform molecular studies of tumor cells aimed to clarify the role of the TP53 gene and other genetic pathways in these tumors. They aim to obtain relevant biological material from participants with adrenocortical tumor (ACT), their biological parents, and relatives for determination of the TP53 germline status, molecular studies of the TP53 gene, and other molecular pathways. Read Less
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/17/2025
Locations: Stanford University, Stanford, California
Cook Children's Medical Center, Fort Worth, Texas
Conditions: Adrenocortical Tumor
Neuroblastoma Biology Study
Recruiting
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma... Read More
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy. Read Less
Gender:
ALL
Ages:
Between 31 days and 99 years
Trial Updated:
09/01/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas
Conditions: Neuroblastoma
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Recruiting
This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.
This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
04/17/2024
Locations: Children's of Alabama, Birmingham, Alabama
Cook Children's Medical Center, Fort Worth, Texas
Conditions: Infusion Reactions
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
Recruiting
Low blood sugars are known to cause brain damage in newborn babies. One of the most common causes of low blood sugars persisting beyond the new born period is a condition called congenital hyperinsulinism (HI). This is a disease whereby the pancreas secretes too much insulin and causes low blood sugars. Twenty to forty percent of these babies will have brain damage. There are two forms of this disease. In one form only a small part of the pancreas makes too much insulin (focal HI) and in the oth... Read More
Low blood sugars are known to cause brain damage in newborn babies. One of the most common causes of low blood sugars persisting beyond the new born period is a condition called congenital hyperinsulinism (HI). This is a disease whereby the pancreas secretes too much insulin and causes low blood sugars. Twenty to forty percent of these babies will have brain damage. There are two forms of this disease. In one form only a small part of the pancreas makes too much insulin (focal HI) and in the other, the whole pancreas make too much insulin (diffuse HI). Another very similar disease is insulinoma which occurs after birth, but also causes hyperinsulinism. If a surgeon could know which part of the pancreas has the focal lesion he could remove it and cure the patient.
The purpose of this study is to investigate whether a new investigational drug called Fluorodopa F 18, when used with a PET scan, can find the focal lesion and guide the surgeon to remove it, thus curing the patient and preventing further brain damage. Read Less
Gender:
ALL
Ages:
18 years and below
Trial Updated:
07/15/2024
Locations: Cook Children's Medical Center, Fort Worth, Texas
Cook Children's Medical Center, Fort Worth, Texas
Conditions: Congenital Hyperinsulinism, Insulinoma
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Recruiting
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body,... Read More
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body, where they can damage tissue or form lesions.
For most patients with LCH, standard-of-care vinblastine/prednisone are used as front-line therapy while cytarabine therapy has been used as therapy for patients who develop recurrence. No alternate treatment strategy has been developed for frontline therapy in LCH.
The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH. We will evaluate the utility of an imaging study called a positron emission tomography (PET) scan to more accurately assess areas of LCH involvement not otherwise seen in other imaging studies as well as response to therapy. We also want to identify if genetic and other biomarkers (special proteins in patient's blood and in patient's cancer) relate to the response of patients LCH to study treatment. Read Less
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/01/2024
Locations: Stanford Children's Hospital, Lucile Packard Children's Hospital, Palo Alto, California
Cook Children's Health Care System, Fort Worth, Texas
Conditions: Langerhans Cell Histiocytosis
Gastroschisis Outcomes of Delivery (GOOD) Study
Recruiting
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks o... Read More
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks or observation with a goal of 38 weeks. The primary composite outcome will include stillbirth, neonatal death prior to discharge, respiratory morbidity, and need for parenteral nutrition at 30 days. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Cook Children's Medical Center, Fort Worth, Texas
Conditions: Gastroschisis
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Goodyear, Arizona
GSK Investigational Site, Fort Worth, Texas
Conditions: Neoplasms
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. Read Less
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy. Read Less
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Goodyear, Arizona
GSK Investigational Site, Fort Worth, Texas
Conditions: Neoplasms
Large and Diverse Populations Enhance Paid Clinical Trial Potential
Paid clinical trials for healthy volunteers in Fort Worth are going to be available for virtually all diverse lifestyles and ethnic groups in the region owing to Texas’ ongoing growth, and the availability of participants. Keep in mind that studies often include more than one participant.
So 300+ studies at 20 participants per study come out to 6,000 opportunities; which is actually a lot more than the national average necessary to maintain ongoing medical breakthroughs in the USA. Though much of the population is traditionally Caucasian, Dallas and Fort Worth are very diverse cities. According to the earlier demographic link, around 1 in 3 people speak a non-English language. That reality will influence trials.
CROs Seeking Clinical Trial Participants
For those seeking healthy volunteer paid clinical trials, Fort Worth options are numerous, several key facilities known for hosting such trials include:
Key Breakthroughs in Fort Worth
Fort Worth has so many breakthroughs in medicine, that they have local “innovation planning teams” to help medical advances be properly organized. In fact, there’s a district in town called “Medical City”. Check out these links to get an idea of what the environment is like:
- Medical Innovation Planning Through UTA Team
- Notable Advances Through UT Southwestern
- Medical City Fort Worth
Finding the Best Clinical Trial Options For You
There are numerous Fort Worth paid clinical trial opportunities for those with little time and good health. If you’re interested in helping advance scientific understanding of human health and making a little money while you’re at it, Fort Worth is a fine place to be.